SRC and cancer: For example, the identification that the two SRC inhibitors Dasatinib and Saracatinib are potentially MET inducers, the co-clustering of SRC pY416 with Claudin7, and its large out-degree in the Bayesian network, all corroborate evidence to the importance of SRC activity for regulating EMT during cancer progression.